Accessibility Menu
Cosmo Pharmaceuticals logo

Cosmo Pharmaceuticals(OTC) CMOPF

Market Cap$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-54%
5 Year-12%
1 Year+1%
1 Month-10%
$74.00
-1.40%
-1.05Today
Cosmo Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 74.002026-07-31
Cosmo Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.21%USD 79.752026-07-24
1 month-9.81%USD 82.052026-07-01
3 month-30.2%USD 106.022026-05-01
Year to date-43.14%USD 130.152025-12-31
1 year+0.83%USD 73.392025-07-30
3 year+60.37%USD 46.142023-06-07
5 year-12.39%USD 84.462021-07-06
Since inception-53.95%USD 160.682017-07-31

Cosmo Pharmaceuticals Financials at a Glance

Market Cap

$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€284.67M

Net Income (TTM)

€48.92M

EPS (TTM)

-$0.44

P/E Ratio

-167.38

Dividend

$2.46

Beta (Volatility)

0.17 (Low)

Price

$74.00

Volume

155

Open

$74.44

Previous Close

$74.00

Daily Range

$74.00 - $74.44

52-Week Range

$74.00 - $169.90

Estimated Earnings Date

Mar 24, 2027

CMOPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. is a life sciences company focused on developing and manufacturing innovative pharmaceuticals for gastroenterology, dermatology, and health technology. Headquartered in Dublin, Ireland, the company operates internationally, offering a range of products that leverage advanced technologies, including artificial intelligence.

Products and Services
  • GI Genius: AI-assisted system for real-time detection of colorectal lesions
  • Winlevi: Prescription medication for treating acne vulgaris
  • Lialda: Once-daily mesalamine tablet for ulcerative colitis remission
Growth Outlook
  • Strong pipeline with multiple products in various clinical trial phases
  • Recent advancements in AI technology enhance product offerings
  • Expansion into new markets expected to drive revenue growth
Financial Highlights
  • Recent quarterly revenue of €52.5 million, showing consistent demand
  • Trailing twelve months (TTM) revenue of €130.6 million, indicating growth potential
  • Current ratio of 7.18 suggests strong liquidity position
Cosmo Pharmaceuticals N.V. is positioned in a dynamic sector with a focus on innovative solutions for pressing health issues. The company's diverse product portfolio, including advanced AI technologies, supports its growth strategy. Recent financial performance indicates a solid revenue base, with a strong liquidity position that may facilitate further investments in research and development. The ongoing clinical trials and product advancements suggest a promising future, making the company an interesting prospect for potential investors.
AI Generated • Jul 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

324.5

CEO

Giovanni di Napoli, MBA

Website

www.cosmopharma.com

Headquarters

Dublin, DU D02 KV60, IE

CMOPF Financials

Key Financial Metrics (TTM)

Gross Margin

45.52%

Operating Margin

-13.37%

Net Income Margin

-6.18%

Return on Equity

-1.21%

Return on Capital

-2.16%

Return on Assets

-0.91%

Earnings Yield

-0.60%

Dividend Yield

3.33%

Payout Ratio

-6.93%

Stock Overview

Market Cap

$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.19M

Volume

155

Avg. Volume

296.206

Financials (TTM)

Gross Profit

€206.59M

Operating Income

€46.84M

EBITDA

€75.69M

Operating Cash Flow

€44.09M

Capital Expenditure

-€10.57M

Free Cash Flow

€33.52M

Cash & ST Invst.

€194.19M

Total Debt

€4.30M

Cosmo Pharmaceuticals Performance Analysis

Cosmo Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 107,292,91739.5%
20232023-12-31EUR 100,305,906-6.5%
20242024-12-31EUR 288,582,113187.7%
20252025-12-31EUR 117,568,479-59.3%
Cosmo Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-4.2%
Q22025-06-30-60.4%
Q42025-12-311.6%
Q22026-06-30-5.0%
Cosmo Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 1.10-27.3%
20232023-12-31EUR -0.72N/A
20242024-12-31EUR 8.78N/A
20252025-12-31EUR -0.26N/A
Cosmo Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-27.2%
Q22025-06-30-103.8%
Q42025-12-3123.1%
Q22026-06-30-180.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€49.87M

-63.4%

Gross Profit

€22.17M

-80.4%

Gross Margin

44.45%

N/A

Market Cap

$1.27BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.93M

N/A

Employees

324

N/A

Net Income

-€4.72M

-106.2%

EBITDA

-€2.81M

-103.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€194.19M

+45.6%

Total Debt

€4.30M

+195.8%

Accounts Receivable

€36.49M

+54.3%

Inventory

€13.42M

-3.5%

Long Term Debt

€3.58M

+401.3%

Short Term Debt

€724.18K

-2.3%

Return on Assets

-0.91%

N/A

Return on Invested Capital

-2.05%

N/A

Free Cash Flow

-€9.50M

-109.7%

Operating Cash Flow

-€7.34M

-107.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNTLFGenetic Technologies Limited
$1.00+0.00%
EVOTFEvotec SE
$6.69+0.00%
LJUIFSSY Group Limited
$0.40+0.00%
TCNNFTrulieve Cannabis Corp.
$8.10-2.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About CMOPF

What is the current price of Cosmo Pharmaceuticals?

Cosmo Pharmaceuticals is trading at $74.00 per share.

What is the 52-week range for Cosmo Pharmaceuticals?

Over the past 52 weeks, Cosmo Pharmaceuticals has traded between $74.00 and $169.90.

How much debt does Cosmo Pharmaceuticals have?

As of the most recent reporting period, Cosmo Pharmaceuticals reported total debt of €5.01M.

How much cash does Cosmo Pharmaceuticals have on hand?

Cosmo Pharmaceuticals reported €65.61M in cash and cash equivalents in its most recent financial results.

What is Cosmo Pharmaceuticals’s dividend yield?

Cosmo Pharmaceuticals currently has a dividend yield of 3.33%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services